^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Maxillary Sinus Carcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/08/2021
    Excerpt:
    PRINCIPLES OF SYSTEMIC THERAPY FOR NON-NASOPHARYNGEAL CANCERS (Lip, Oral Cavity, Oropharynx, Hypopharynx, Glottic Larynx, Supraglottic Larynx, Ethmoid Sinus, Maxillary sinus, Occult Primary)...Other Recommended Regimens...Pembrolizumab/platinum (cisplatin or carboplatin)/docetaxel
    Secondary therapy:
    carboplatin + docetaxel; cisplatin + docetaxel